Pioneer POC (point-of-care) company Careside faces some hard choices
This article was originally published in Clinica
No venture capital company - not one - put a single dollar into Careside," says Careside's chairman and CEO, Vickery Stoughton. This wasn't for lack of effort on his part. He says that he talked to some 50 venture companies about investing into Careside's point-of-care blood chemistry analyser, but without success.
You may also be interested in...
Despite seeing an 8% drop in global turnover in 2019, an upbeat Teva says the completion of its restructuring plan has positioned the company to increase its turnover through newly-launched products – including biosimilars, brands and new generics – as well as improve its profit margins through manufacturing optimization.
Japanese big pharma Eisai taps Celgene and Sanofi execs as its new VPs for corporate affairs and market access. And Freeline Therapeutics, developer of gene therapies for bleeding disorders, selects a former Alnylam Pharma SVP as CEO.